2 news items
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
BHVN
REGN
29 May 24
positions Biohaven for future leadership in oncology."
Biohaven is developing a broad portfolio of highly
Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN
2 May 24
, President and Chief Executive Officer of Regeneron. "We had a strong quarter of EYLEA HD uptake, and we are well positioned to continue our leadership
- Prev
- 1
- Next